Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14

Abpro Holdings, Inc.

Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.
Common stock to trade on Nasdaq Global Market under 'ABP'; warrants on Nasdaq Capital Market under 'ABPWW' beginning Nov. 14, 2024.
Celltrion invested $5 million in a PIPE transaction and gained a board seat (Soo Young Lee).
Abpro focuses on next-gen antibody therapies for HER2+ cancers, Wet AMD/DME, and COVID-19 using DiversImmune platform.
Exclusive collaboration with Celltrion on ABP 102 (t-cell engager) for HER2+ breast, gastric, and pancreatic cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.